Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 18,269 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Controlled Group Clear all

Conditions: Acute Kidney Injury
Interventions: Care delivery algorithim; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
Interventions: Omadacycline Oral Tablet, Placebo; Drug
Lead sponsor: Paratek Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 17
States / cities: Stanford, California • Washington D.C., District of Columbia • Clearwater, Florida + 14 more

Conditions: Parkinson Disease
Interventions: pramipexole; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 30 Years to 79 Years
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 32
States / cities: Brimingham, Alabama • Scottsdale, Arizona • La Jolla, California + 28 more

Conditions: Migraine
Interventions: Dietary training; Behavioral
Lead sponsor: American University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Reversible Pulpitis, Dental Pulp Diseases
Interventions: NeoMTA, ProRoot MTA; Biological · Other
Lead sponsor: Texas A & M University Baylor College Of Dentistry; Other
Eligibility: 2 Years to 8 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 841 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Coral Gables, Florida • Savannah, Georgia • Evansville, Indiana + 5 more

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: BEKINDA, Placebo; Drug
Lead sponsor: RedHill Biopharma Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 16
States / cities: Huntsville, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 12 more

Conditions: Pain, BPH With Urinary Obstruction, BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms
Interventions: Ibuprofen 600 mg, Education; Drug · Behavioral
Lead sponsor: Benaroya Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Health Insurance
Interventions: Kentucky HEALTH; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 64 Years
Enrollment: 378,828 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Frankfort, Kentucky • Bethesda, Maryland

Conditions: Postoperative Quality of Recovery
Interventions: Opioid Free Total Intravenous Anesthesia, Total Intravenous anesthesia with opioid; Combination Product
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Arthroscopic Shoulder Surgery, Pain, Postoperative
Interventions: Extracellular Matrix Graft Injectable Implant; Device
Lead sponsor: Brian Badman; Other
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Avon, Indiana

Conditions: Contraceptive Use
Interventions: Conecta Familia, Contraceptive need survey; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Disability Physical, Cognitive Impairment
Interventions: Modified FE-SaLiR, Unmodified Chinese Medicine Exercise, Active Control; Behavioral
Lead sponsor: The University of Texas at San Antonio; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Solid Tumors
Interventions: Indium In-111 pentetreotide; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 4
States / cities: Miami, Florida • Iowa City, Iowa • New Orleans, Louisiana + 1 more

Conditions: Diabetes Mellitus
Interventions: Phase 1- Introduction to Dexcom G6 CGM; Device
Lead sponsor: DexCom, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Henderson, Nevada

Conditions: Obesity/Overweight
Interventions: ALT-801, Placebo; Drug · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 31
States / cities: Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 25 more

Conditions: Preterm Premature Rupture of the Membranes, Pregnancy Complications, Pregnancy, High Risk
Interventions: Ambulation Group, Routine Care; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 12 Years to 55 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypercholesterolemia
Interventions: BMS-201038 (AEGR-733), Ezetimibe; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Obesity
Interventions: Daily self-weighing (DSW); Device
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years to 75 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Health Behavior
Interventions: Hydrate Philly; Behavioral
Lead sponsor: Philadelphia Department of Public Health; Government
Eligibility: 3 Years to 100 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Diabetes LIVE JustICE, Enhanced Education; Other
Lead sponsor: Louise Reagan; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Storrs, Connecticut • Storrs Mansfield, Connecticut

Conditions: Behavioral
Interventions: Behavioral Advisory System, Behavioral Treatment, Behavioral Division; Behavioral · Drug · Device
Lead sponsor: Brian Bolden; Other
Eligibility: 19 Years to 40 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Malaria
Interventions: MAM01 1.5 mg/kg, Placebo, MAM01 5 mg/kg, MAM01 10 mg/kg, MAM01 40 mg/kg, MAM01 450 mg, Control, MAM01 600 mg, MAM01 900 mg; Biological · Other
Lead sponsor: Gates Medical Research Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: Sequestration; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Acute Kidney Injury Standardized Clinical Assessment and Management Plan for Renal Replacement Initiation

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

Dietary Intervention for Migraine Relief

Success and Color Stability of MTA Pulpotomized Primary Molars: an RCT

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Optimizing Pain Control in Transurethral Resection of the Prostate

Evaluation of the Health and Economic Consequences of Kentucky's Section 1115 Demonstration Waiver

Opioid Free Anesthesia and Bariatric Surgery

Examining the Effectiveness of a Connective Tissue Matrix Implant in Reducing Post-operative Pain and Narcotic After Outpatient Arthroscopic Shoulder Surgery

Utilizing Pediatric Primary Care Connections to Advance Reproductive Health

FE-SaLiR: Function Improvement Exercise

Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors

Assessing Non-adjunctive CGM Safety at Home and in New Markets

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Ambulation for Latency During Expectant Management of PPROM

The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia

Daily Self-weighing and Holiday-associated Weight Gain in Adults

Increasing Water Access and Appeal in Community Recreation Centers

Diabetes Learning in Virtual Environments Just in Time for Community Reentry

Behavioral Studies and Practices

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

A Study of Exclusion Criteria in a University Population